About Laminar Pharma
Laminar Pharma is a Healthcare company based in Palma (Spain) founded in 2006. Melipathy-based drugs are developed for cancer, Alzheimers, and inflammation treatments. Laminar Pharma has raised $14.71 million across 5 funding rounds from investors including European Union, Fundación Alba Pérez and Dentol Capital. Laminar Pharma offers products and services including LAM561, LAM226, and LAM204. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Laminar Pharmaceuticals S.A.
Company details
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimers, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
- Headquarters Palma, Spain
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website laminarpharma.com
- Social LinkedIn X
- Legal Name Laminar Pharmaceuticals S.A.
- Total Equity Funding$14.71M (USD)
in 5 rounds
- Latest Funding Round$6.27M (USD), Series A
Jul 2024
- InvestorsEuropean Union
& 3 more
Products & Services of Laminar Pharma
Laminar Pharma offers a comprehensive portfolio of products and services, including LAM561, LAM226, and LAM204.
Drug for glioblastoma treatment in clinical trials
Molecule targeting specific diseases like cancers
Innovative compound for unmet medical needs
Funding Insights of Laminar Pharma
Laminar Pharma has successfully raised a total of $14.71M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $6.27 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.71M
- Total Rounds 5
- Last Round Series A — $6.27M
- First Round $3.07M
(Dec 2017)
- Investors Count 4
All 5 funding rounds of Laminar Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $6.27M | Series A | – | Fundacionalbaperez, Matutes family | |
| Oct 2023 | $8.44M | Series A | – | – | |
| Nov 2022 | $280,525 | Grant | – | – | |
| Apr 2021 | $189,400 | Grant | – | – | |
| Dec 2017 | $3.07M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Laminar Pharma
Laminar Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Fundación Alba Pérez and Dentol Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| matutesfamily.tcc.mode | ||||
Funds are raised by Fundación Alba Pérez for childhood cancer research. | fundacionalbaperez.org | L’Hospitalet de Llobregat, Spain | ||
| dentolcapital.tcc.mode | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Laminar Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Laminar Pharma
10 people are tracked at Laminar Pharma (4 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Adrian Gerald McNicholl | Chief of Clinical Operations: Clinical Trials, Market Access, Medical Affairs | Leadership |
Paula Fernández García | Chief Scientific Officer | Leadership |
Catalina Ana Rosselló Castillo | Head Of Department Chemistry Manufacturing Controls | Leadership |
David Roberto | Chief Financial Officer | Leadership |
Gema Malet | Senior Scientist Oncology | Team |
Lourdes Iglesias | Clinical Project Manager Oversight | Team |
Javier Fernández Díaz | Business Development Manager / CSO Associate | Team |
Victoria Llado Canellas | USA CSO And Strategy | Team |
Raquel Rodríguez Lorca | Phd Researcher | Team |
Marta Salvador Castell | Postdoctoral Researcher | Team |
Complete people profiles for Laminar Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Laminar Pharma
3 dated milestones of Laminar Pharma across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Laminar Pharma is founded.
- Funding First funding round of $3.1M.
- Funding Latest funding round, Series A, of $6.3M.
Web traffic of Laminar Pharma
The website of Laminar Pharma (laminarpharma.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 5.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Laminar Pharma
Complete news archive for Laminar Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laminar Pharma
Laminar Pharma was founded in 2006 and raised its 1st funding round 11 years after it was founded.
Laminar Pharma is headquartered in Palma, Spain. It is registered at Palma, Balearic Islands, Spain.
Laminar Pharma is a funded company, having raised a total of $14.71M across 5 funding rounds to date. The company's 1st funding round was a Grant of $3.07M, raised on Dec 2017.
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimers, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
Laminar Pharma offers LAM561, LAM226, and LAM204.
Laminar Pharma has 4 investors. Key investors include European Union, Fundación Alba Pérez, Dentol Capital, and Matutes family.
Laminar Pharma operates through Laminar Pharmaceuticals S.A..